

Azure Health Technology Ltd

(to be renamed VGI Health Technology)

Focused on nutraceutical and pharma opportunities

Azure Health Technology (soon to be renamed VGI Health Technology, post an extraordinary general meeting scheduled for 9th July) listed on the NSX in May 2021 after raising \$2.5m at \$0.20/share to give a market capitalisation at listing of \$27.4m. The company was previously listed on the ASX (in 2007), but delisted on 1st May 2020 and in the following month acquired Invictus Biopharma Ltd. Invictus Biopharma delivered an experienced group of board members and executives and two drug delivery technologies which fit well with Vitamin E (tocotrienols) nutraceutical products and prescription medicines. VTL is launching two patented nutraceutical products, NE1-Elite® for reduction of Delayed Onset Muscle Soreness and muscle recovery and NE1-Heart® for the maintenance of heart health. VTL sells nutraceuticals based on its improved delivery platform for tocotrienols and is also developing a pipeline of four drug candidates addressing indications with great unmet needs, Pancreatic Cancer and Non-Alcoholic Fatty Liver Disease (NAFLD). The company has appointed US manufacturers for the nutraceutical products and is about to commence Phase II clinical studies on the Cancer and NAFLD drug candidates. VTL will build shareholder value by generating sales revenues from its nutraceuticals business while at the same time advancing the drug development program to efficacy data readouts for two Phase II clinical studies in pancreatic cancer and NAFLD within the next 18 to 24 months.

Business model

VTL is pursuing two business channels focusing on “evidence-based nutraceuticals” and prescription medicines based on improved delivery of Tocotrienol based drugs. The two business channels have different paths to commercialisation. The US nutraceutical business is a consumer-based sports nutrition and heart health market which will generate short-term revenues. The prescription medicine business will target licensing transactions with pharmaceutical companies after completing Phase II proof of concept studies and completing efficacy data readouts. The first US manufacturing run was completed in Q1 of 2021 and these finished products have now been received in VTL’s Florida-based subsidiary, Invictus Nutraceuticals, Inc. The launch of these nutraceutical products has commenced in the US. VTL intends to partner with large pharmaceutical companies which can take drug candidates to market after proof of concept (whether the drugs are efficacious or not) has been established. Retail distribution of the nutraceutical products is expected to be announced in H2 of 2021.

Recent News

Funds raised from the NSX IPO in May are intended to assist in commercialising the nutraceutical products as sports nutrition products and advancing the two Phase II trials to commencement of dosing of patients. VTL expects distribution channels to launch in H2 2022. In early June VTL confirmed the appointment of an additional licenced manufacturer in the US which will supply finished nutraceutical products for sale in the US and internationally and clinical study drugs for the two phase II clinical studies for the Cancer and Liver drugs.

Pro-forma earnings history AUD

Year end	Revenue	EBITDA	PBT	NPAT	EPS (c)	OCF	EV//EBITDA (x)	P/E (x)
Jun 2019	3.3	2.75	(2.75)	(2.75)	3.95	(0.6)	n.a.	n.a.
Jun 2020	0	(1.42)	(1.42)	(1.42)	(1.95)	(2.1)	n.a.	n.a.
Half Year								
Dec 2020	0	(1.34)	(1.34)	(1.34)	(1.28)	(1.2)	n.a.	n.a.

Source: Prospectus, Company data *Based on shares at the time of reporting

Shares Summary

Share Code	VTL
Share price	\$0.24
Market Capitalisation	\$32.9M
Number of Shares	137.2M
Est. Net Cash post IPO	\$1.0M
Share Registry	Link Market Services Ltd

RaaS 5-Point Score* = 0/5

Revenue increasing (0); EPS increasing (0), Return on Capital Employed [ROCE] (0); EBIT interest cover >3x (0) Gross Operating cash flow/EBITDA >90%(0)

Upside Case

- Successful generation of sales revenues from nutraceutical products in the US & internationally
- Execution of partnership transactions with major pharmaceutical companies for the cancer and NAFLD drugs
- Phase II clinical studies result in positive efficacy data readouts in 18-24 months

Downside Case

- Slow progress in distribution strategy
- Delays in phase II trials
- May not secure large pharma deals for its Cancer & NALFD drug candidates

Board of Directors and Management

Chairman	Mr Lou Panaccio
CEO	Dr Glenn Tong
Director	Mr Jiayi (Steven) Yu
CFO	Mr Ian Forbes
CSO	Dr David Kingston
President & CEO Invictus Nutraceuticals, Inc. (US)	Mr Richard Estalella

Catalysts

- Interest from an established pharmaceutical company
- US nutraceutical distributorships signed

Comparable Companies

Invex Therapeutics(ASX: IXC.ASX), Hexima Ltd.(ASX:HXL), Wellfully Ltd.(ASX:WFL)

RaaS Advisory contacts

Scott Maddock	+61 418 212 625 scott.maddock@raasgroup.com
Finola Burke	+61 414 354 712 finola.burke@raasgroup.com

This report has been commissioned by NSX Ltd (“NSX”) and prepared and issued by RaaS Advisory Pty Ltd, trading as Research as a Service. This report has been prepared independently of NSX and does not represent the opinion of NSX. NSX makes no representation in relation to acquiring, disposing of or otherwise dealing in the securities referred to in this report.

RaaS Advisory received a fee for preparation of this report. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however neither NSX nor RaaS Advisory guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the principals of RaaS Advisory at the time of publication. This research is issued in Australia by RaaS Advisory and any access to it should be read in conjunction with the Financial Services Guide on the following two pages. RaaS Advisory holds Corporate Authorised Representative no 1248415 of AFSL 456663. This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. Past performance is not a guarantee of future performance. To the maximum extent permitted by law, RaaS Advisory, its affiliates, the respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. Copyright 2021 RaaS Advisory Pty Ltd (A.B.N. 99 614 783 363). All rights reserved.



FINANCIAL SERVICES GUIDE

RaaS Advisory Pty Ltd
ABN 99 614 783 363
Corporate Authorised Representative, number 1248415

of

BR SECURITIES AUSTRALIA PTY LTD
ABN 92 168 734 530
AFSL 456663

Effective Date: 6th May 2021



About Us

BR Securities Australia Pty Ltd (BR) is the holder of Australian Financial Services License ("AFSL") number 456663. RaaS Advisory Pty Ltd (RaaS) is an Authorised Representative (number 1248415) of BR.

This Financial Service Guide (FSG) is designed to assist you in deciding whether to use RaaS's services and includes such things as

- who we are
- our services
- how we transact with you
- how we are paid, and
- complaint processes

Contact Details, BR and RaaS

BR Head Office: Suite 5GB, Suite 5GB, Level 5, 33 Queen Street, Brisbane, QLD, 4000

RaaS: 20 Halls Road Arcadia, NSW 2159

P: +61 414 354712

E: finola.burke@raasgroup.com

RaaS is the entity providing the authorised AFSL services to you as a retail or wholesale client.

What Financial Services are we authorised to provide? RaaS is authorised to

- provide general advice to retail and wholesale clients in relation to
 - Securities
- deal on behalf of retail and wholesale clients in relation to
 - Securities

The distribution of this FSG by RaaS is authorized by BR.

Our general advice service

Please note that any advice given by RaaS is general advice, as the information or advice given will not take into account your particular objectives, financial situation or needs. You should, before acting on the advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Prospectus, Product Disclosure Statement or like instrument. As we only provide general advice we will not be providing a Statement of Advice. We will provide you with recommendations on securities

Our dealing service

RaaS can arrange for you to invest in securities issued under a prospectus by firstly sending you the offer document and then assisting you fill out the application from if needed.

How are we paid?

RaaS earns fees for producing research reports. Sometimes these fees are from companies for producing research reports and/or a financial model. When the fee is derived from a company, this is clearly highlighted on the front page of the report and in the disclaimers and disclosures section of the report.

We may also receive a fee for our dealing service, from the company issuing the securities.

Associations and Relationships

BR, RaaS, its directors and related parties have no associations or relationships with any product issuers other than when advising retail clients to invest in managed funds when the managers of these funds may also be clients of BR. RaaS's representatives may from time to time deal in or otherwise have a financial interest in financial products recommended to you but any material ownership will be disclosed to you when relevant advice is provided.

Complaints

If you have a complaint about our service you should contact your representative and tell them about your complaint. The representative will follow BR's internal dispute resolution policy, which includes sending you a copy of the policy when required to. If you aren't satisfied with an outcome, you may contact AFCA, see below.

BR is a member of the Australian Financial Complaints Authority (AFCA). AFCA provide fair and independent financial services complaint resolution that is free to consumers.

Website: www.afca.org.au; Email: info@afca.org.au; Telephone: 1800931678 (free call)
In writing to: Australian Financial Complaints Authority, GPO Box 3, Melbourne, VIC, 3001.

Professional Indemnity Insurance

BR has in place Professional Indemnity Insurance which satisfies the requirements for compensation under s912B of the Corporations Act and that covers our authorized representatives.